JPWO2020120981A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020120981A5 JPWO2020120981A5 JP2021533609A JP2021533609A JPWO2020120981A5 JP WO2020120981 A5 JPWO2020120981 A5 JP WO2020120981A5 JP 2021533609 A JP2021533609 A JP 2021533609A JP 2021533609 A JP2021533609 A JP 2021533609A JP WO2020120981 A5 JPWO2020120981 A5 JP WO2020120981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide ligand
- mmp
- drug conjugate
- aspects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 description 16
- 239000003446 ligand Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 6
- 102000011716 Matrix Metalloproteinase 14 Human genes 0.000 description 5
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000002062 molecular scaffold Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Description
本発明の選択されたペプチドを上述のヒト蛍光偏光競合結合アッセイで試験した。結果は、表1に示されている
表1:ヒトMT1-MMP蛍光偏光競合結合
(態様1)
少なくとも2つのループ配列によって隔てられた少なくとも3つのシステイン残基を含むポリペプチド及び該ポリペプチドのシステイン残基と共有結合を形成する非芳香族分子スキャフォールドを含み、その結果、少なくとも2つのポリペプチドループが該分子スキャフォールド上に形成される、MT1-MMPのコラーゲン結合部位に特異的なペプチドリガンド。
(態様2)
前記ループ配列が6つのアミノ酸を含む、態様1記載のペプチドリガンド。
(態様3)
前記ループ配列が、その両方が6つのアミノ酸からなる2つのループ配列で隔てられた3つのシステイン残基を含む、態様1又は態様2記載のペプチドリガンド。
(態様4)
前記ペプチドリガンドが、
(化1)
(ここで、C
i
、C
ii
、及びC
iii
は、それぞれ、第一、第二、及び第三のシステイン残基を表す)
:から選択されるアミノ酸配列又はその医薬として許容し得る塩を含む、態様1~3のいずれか一項記載のペプチドリガンド。
(態様5)
前記
(化2)
のペプチドリガンドが、
(化3)
例えば:
A-(配列番号2)-A(BCY1026);
A-(配列番号3)-A(BCY1057);
A-(配列番号4)-A(BCY1065);
A-(配列番号5)-A(BCY1067);
A-(配列番号6)-A(BCY1073);
A-(配列番号7)-A(BCY1074);
A-(配列番号8)-A(BCY1075);及び
A-(配列番号9)-A(BCY1076)
:から選択される、態様4記載のペプチドリガンド。
(態様6)
前記分子スキャフォールドがTATAである、態様1~5のいずれか一項記載のペプチドリガンド。
(態様7)
前記分子スキャフォールドがTATAであり、前記
(化4)
のペプチドリガンドが、
A-(配列番号2)-A(BCY1026);
A-(配列番号3)-A(BCY1057);
A-(配列番号4)-A(BCY1065);
A-(配列番号5)-A(BCY1067);
A-(配列番号6)-A(BCY1073);
A-(配列番号7)-A(BCY1074);
A-(配列番号8)-A(BCY1075);及び
A-(配列番号9)-A(BCY1076)
:から選択される、態様6記載のペプチドリガンド。
(態様8)
前記医薬として許容し得る塩が、遊離酸又はナトリウム、カリウム、カルシウム、アンモニウム塩から選択される、態様1~7のいずれか一項記載のペプチドリガンド。
(態様9)
前記MT1-MMPがヒトMT1-MMPである、態様1~8のいずれか一項記載のペプチドリガンド。
(態様10)
1以上のエフェクター及び/又は官能基にコンジュゲートされた、態様1~9のいずれか一項記載のペプチドリガンドを含む薬物コンジュゲート。
(態様11)
1以上の細胞毒性剤にコンジュゲートされた、態様10記載の薬物コンジュゲート。
(態様12)
前記細胞毒性剤がMMAE又はDM1から選択される、態様11記載の薬物コンジュゲート。
(態様13)
態様1~9のいずれか一項記載のペプチドリガンド又は態様10~12のいずれか一項記載の薬物コンジュゲートを1以上の医薬として許容し得る賦形剤との組合せで含む、医薬組成物。
(態様14)
1以上の治療剤をさらに含む、態様13記載の医薬組成物。
(態様15)
MT1-MMPによって媒介される疾患又は障害の予防、抑制、又は治療において使用するための、態様10~12のいずれか一項記載の薬物コンジュゲート。
Selected peptides of the invention were tested in the human fluorescence polarization competitive binding assay described above. Results are shown in Table 1: Human MT1-MMP fluorescence polarization competitive binding.
(Aspect 1)
A polypeptide comprising at least three cysteine residues separated by at least two loop sequences and a non-aromatic molecular scaffold that forms covalent bonds with the cysteine residues of said polypeptide, resulting in at least two polypeptide loops. is formed on the molecular scaffold, a peptide ligand specific for the collagen binding site of MT1-MMP.
(Aspect 2)
2. The peptide ligand of embodiment 1, wherein said loop sequence comprises 6 amino acids.
(Aspect 3)
3. A peptide ligand according to embodiment 1 or embodiment 2, wherein said loop sequence comprises three cysteine residues separated by two loop sequences, both of which consist of six amino acids.
(Aspect 4)
wherein the peptide ligand is
(Chem. 1)
(where C i , C ii and C iii represent the first, second and third cysteine residues respectively)
4. A peptide ligand according to any one of embodiments 1-3, comprising an amino acid sequence selected from: or a pharmaceutically acceptable salt thereof.
(Aspect 5)
Said
(Chemical 2)
The peptide ligand of
(Chemical 3)
for example:
A-(SEQ ID NO:2)-A(BCY1026);
A-(SEQ ID NO:3)-A(BCY1057);
A-(SEQ ID NO:4)-A(BCY1065);
A-(SEQ ID NO:5)-A(BCY1067);
A-(SEQ ID NO:6)-A(BCY1073);
A-(SEQ ID NO:7)-A(BCY1074);
A-(SEQ ID NO:8)-A(BCY1075); and
A-(SEQ ID NO:9)-A(BCY1076)
A peptide ligand according to embodiment 4, which is selected from:
(Aspect 6)
6. The peptide ligand according to any one of embodiments 1-5, wherein said molecular scaffold is TATA.
(Aspect 7)
wherein said molecular scaffold is TATA;
(Chem. 4)
The peptide ligand of
A-(SEQ ID NO:2)-A(BCY1026);
A-(SEQ ID NO:3)-A(BCY1057);
A-(SEQ ID NO:4)-A(BCY1065);
A-(SEQ ID NO:5)-A(BCY1067);
A-(SEQ ID NO:6)-A(BCY1073);
A-(SEQ ID NO:7)-A(BCY1074);
A-(SEQ ID NO:8)-A(BCY1075); and
A-(SEQ ID NO:9)-A(BCY1076)
A peptide ligand according to embodiment 6, which is selected from:
(Aspect 8)
The peptide ligand according to any one of embodiments 1-7, wherein said pharmaceutically acceptable salt is selected from the free acid or sodium, potassium, calcium, ammonium salts.
(Aspect 9)
9. The peptide ligand according to any one of embodiments 1-8, wherein said MT1-MMP is human MT1-MMP.
(Mode 10)
A drug conjugate comprising a peptide ligand according to any one of aspects 1-9 conjugated to one or more effector and/or functional groups.
(Aspect 11)
A drug conjugate according to embodiment 10, conjugated to one or more cytotoxic agents.
(Aspect 12)
12. The drug conjugate according to embodiment 11, wherein said cytotoxic agent is selected from MMAE or DM1.
(Aspect 13)
A pharmaceutical composition comprising a peptide ligand according to any one of aspects 1-9 or a drug conjugate according to any one of aspects 10-12 in combination with one or more pharmaceutically acceptable excipients.
(Aspect 14)
14. The pharmaceutical composition according to embodiment 13, further comprising one or more therapeutic agents.
(Aspect 15)
A drug conjugate according to any one of aspects 10-12 for use in the prevention, suppression or treatment of a disease or disorder mediated by MT1-MMP.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1820288.7 | 2018-12-13 | ||
GBGB1820288.7A GB201820288D0 (en) | 2018-12-13 | 2018-12-13 | Bicycle peptide ligaands specific for MT1-MMP |
PCT/GB2019/053537 WO2020120981A1 (en) | 2018-12-13 | 2019-12-13 | Bicyclic peptide ligands specific for mt1-mmp |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022512478A JP2022512478A (en) | 2022-02-04 |
JPWO2020120981A5 true JPWO2020120981A5 (en) | 2022-12-19 |
Family
ID=65146942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021533609A Pending JP2022512478A (en) | 2018-12-13 | 2019-12-13 | Bicyclic peptide ligand specific for MT1-MMP |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220362390A1 (en) |
EP (1) | EP3894009A1 (en) |
JP (1) | JP2022512478A (en) |
KR (1) | KR20210123296A (en) |
CN (1) | CN113474047A (en) |
AU (1) | AU2019398722A1 (en) |
BR (1) | BR112021011217A2 (en) |
CA (1) | CA3122659A1 (en) |
EA (1) | EA202191651A1 (en) |
GB (1) | GB201820288D0 (en) |
IL (1) | IL283874A (en) |
MX (1) | MX2021006989A (en) |
SG (1) | SG11202106082TA (en) |
WO (1) | WO2020120981A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11730819B2 (en) | 2016-12-23 | 2023-08-22 | Bicycletx Limited | Peptide derivatives having novel linkage structures |
WO2023088236A1 (en) * | 2021-11-16 | 2023-05-25 | 海思科医药集团股份有限公司 | Bicyclic peptide ligand of mt1-mmp and conjugate thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2257624E (en) | 2008-02-05 | 2012-05-29 | Medical Res Council | Methods and compositions |
PL3215518T3 (en) | 2014-10-29 | 2021-08-23 | Bicyclerd Limited | Bicyclic peptide ligands specific for mt1-mmp |
US10624968B2 (en) * | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
GB201706477D0 (en) * | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
-
2018
- 2018-12-13 GB GBGB1820288.7A patent/GB201820288D0/en not_active Ceased
-
2019
- 2019-12-13 EP EP19824379.2A patent/EP3894009A1/en active Pending
- 2019-12-13 WO PCT/GB2019/053537 patent/WO2020120981A1/en unknown
- 2019-12-13 BR BR112021011217-0A patent/BR112021011217A2/en unknown
- 2019-12-13 MX MX2021006989A patent/MX2021006989A/en unknown
- 2019-12-13 CA CA3122659A patent/CA3122659A1/en active Pending
- 2019-12-13 CN CN201980081542.7A patent/CN113474047A/en active Pending
- 2019-12-13 US US17/309,631 patent/US20220362390A1/en active Pending
- 2019-12-13 JP JP2021533609A patent/JP2022512478A/en active Pending
- 2019-12-13 EA EA202191651A patent/EA202191651A1/en unknown
- 2019-12-13 SG SG11202106082TA patent/SG11202106082TA/en unknown
- 2019-12-13 KR KR1020217021607A patent/KR20210123296A/en unknown
- 2019-12-13 AU AU2019398722A patent/AU2019398722A1/en active Pending
-
2021
- 2021-06-10 IL IL283874A patent/IL283874A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10940182B2 (en) | Use of modified vasoactive intestinal peptides in the treatment of hypertension | |
JPH03118333A (en) | Fibrinogen receptor antagonist | |
JP2019533722A5 (en) | ||
JP6495270B2 (en) | Pharmaceutical composition containing a neuroprotective peptide | |
JP2003503312A5 (en) | ||
JP2023029957A (en) | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation | |
JP2020524163A5 (en) | Peptide composition | |
KR20190062496A (en) | Dosage regimen for controlled-release PTH compound | |
JPWO2021019243A5 (en) | ||
JP2010209088A (en) | Compound binding to p-selectin | |
JPWO2021019244A5 (en) | ||
JP2012517425A5 (en) | ||
JP2019500417A (en) | Histatin and its use | |
CN110799547B (en) | Compounds for treating, ameliorating or preventing neurological-related disorders and uses thereof | |
JPWO2020120981A5 (en) | ||
JP6046060B2 (en) | Novel conjugate molecule comprising a CD4 receptor-derived peptide bound to a polyanionic polypeptide for the treatment of AIDS | |
JPWO2020128526A5 (en) | ||
JPWO2020120984A5 (en) | ||
JPWO2020120979A5 (en) | ||
JPWO2020120983A5 (en) | ||
CN113412116A (en) | Modified axon growth-attractant factor-1 peptides and compositions for cardioprotection | |
JPWO2020120978A5 (en) | ||
JPWO2020148526A5 (en) | ||
JPWO2020128527A5 (en) | ||
JPWO2020148525A5 (en) |